- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07947160
High-flow Nasal Oxygenation in Obese Patients During Colonoscopy: a Randomized Controlled Trial (COCOON) (COCOON)
High-flow Nasal Oxygenation in Obese Patient During Colonoscopy: a Randomized Controlled Trial: the COCOON Trial
The goal of this clinical trial is to determine whether high-flow oxygen therapy (HFOT) is more effective than conventional oxygen therapy (COT) in reducing episodes of intraoperative oxygen desaturation (oxygen saturation [SpO2] ≤ 90%) during colonoscopy under general anesthesia in adults with a body mass index (BMI) of 30 kg/m² or higher.
The main question it aims to answer is:
Does high-flow oxygen therapy reduce the occurrence of intraoperative oxygen desaturation compared with conventional oxygen therapy during colonoscopy under general anesthesia? Researchers will compare high-flow oxygen therapy with conventional oxygen therapy to determine whether high-flow oxygen therapy reduces the occurrence of intraoperative oxygen desaturation.
Participants will:
Be screened during their anesthesia consultation between 60 days and 48 hours before the scheduled colonoscopy.
Be randomly assigned (1:1) to receive either conventional oxygen therapy or high-flow oxygen therapy. Receive standard monitoring and 3 minutes of pre-oxygenation according to their assigned treatment group.
Undergo colonoscopy under general anesthesia while breathing spontaneously. Be monitored for oxygen desaturation during the procedure. Have ventilatory and hemodynamic data recorded during the procedure and collected immediately after the colonoscopy.
The study will include adults scheduled for a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Prospective, multicentre, controlled, randomized, parallel-group superiority trial with a 1:1 allocation ratio, with participants blinded to the oxygen treatment received, comparing high-flow oxygen therapy (HFOT) with conventional oxygen therapy (COT) delivered through an oxygen mask. The study aims to determine whether HFOT is more effective than COT in preventing intraoperative oxygen desaturation during colonoscopy under general anesthesia in participants with a body mass index (BMI) of 30 kg/m² or higher.
Adults with a body mass index (BMI) of 30 kg/m² or higher who are scheduled to undergo a colonoscopy at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
After written informed consent has been obtained, participants will be randomized by the study investigators to one of the two treatment groups: conventional oxygen therapy (COT); high-flow oxygen therapy (HFOT).
A computer-generated randomization list with a 1:1 allocation ratio and variable block sizes will be prepared by a statistician from the URC Paris Nord Secteur Ouest, in accordance with the sponsor's procedures. Allocation will be concealed, as the randomization list will not be accessible to the study team. The list will be directly integrated into CleanWEB™, a secure, centralized, 24- hour Internet platform, which will also be used for the electronic case report form (eCRF).
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jules STERN
- Telefoonnummer: +33140258080
- E-mail: jules.stern@aphp.fr
Studie Contact Back-up
- Naam: Ines CHIBANE, +33140257961
- E-mail: ines.chibane@aphp.fr
Studie Locaties
-
-
-
Clichy, Frankrijk, 92110
- Hôpital Beaujon, département d'anesthésie-réanimation, 100 boulevard du Général Leclerc
-
Contact:
- Stéphanie SIGAUT, Principal Investigator
-
Colombes, Frankrijk, 92700
- Hôpital Louis Mourier, département d'anesthésie-réanimation, 178 rue des Renouillers
-
Paris, Frankrijk, 75018
- Hôpital Bichat-Claude Bernard, département d'anesthésie-réanimation, 46 rue Henri Huchard
-
Contact:
- Jules STERN, Principal Investigator
- Telefoonnummer: +33140258080
- E-mail: jules.stern@aphp.fr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 years or older.
- Body mass index (BMI) of 30 kg/m² or higher.
- Scheduled to undergo a colonoscopy under general anesthesia with spontaneous breathing at Bichat-Claude Bernard Hospital, Beaujon Hospital, or Louis Mourier Hospital.
- Affiliated with a social security scheme.
- Free, informed and written consent signed.
Exclusion Criteria:
-
Colonoscopy in a participant at high risk of aspiration requiring orotracheal intubation, defined by at least one of the following:
- Symptomatic or severe gastroesophageal reflux disease, notably with frequent regurgitation (≥ 2 episodes per week), mainly occurring in the supine position;
- Hiatal hernia;
- History of bariatric surgery (sleeve gastrectomy, gastric bypass);
- Neurodegenerative disease requiring airway protection during colonoscopy.
-
Emergency colonoscopy.
-
Chronic respiratory failure.
-
Severe heart failure.
-
Allergy to propofol.
-
Pregnant or breastfeeding woman.
-
Adult under legal protection (guardianship or curatorship).
-
Beneficiary of State Medical Aid (Aide Médicale de l'État, AME).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Conventional oxygen therapy
Participants assigned to the conventional oxygen therapy group will receive 100% oxygen at 6 L/min through an oxygen capnography mask during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously. |
100% oxygen delivered at a flow rate of 6 L/min through an oxygen capnography mask, during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.
Andere namen:
|
|
Experimenteel: High-flow oxygen therapy
Participants assigned to the high-flow oxygen therapy group will receive 100% oxygen at 50 L/min through an Optiflow® system (Fisher & Paykel Healthcare) during the 3-minute pre-oxygenation period and throughout the procedure. After pre-oxygenation, propofol will be administered by target-controlled intravenous infusion, with an initial target concentration of 2 µg/mL. The anesthetist may adjust the target concentration to achieve deep sedation according to American Society of Anesthesiologists (ASA) criteria. The colonoscopy will be performed while participants breathe spontaneously. |
100% oxygen delivered at a flow rate of 50 L/min through an Optiflow® high-flow nasal system (Fisher & Paykel Healthcare), during the 3-minute pre-oxygenation period and throughout the colonoscopy performed under general anesthesia (propofol target-controlled infusion) with spontaneous breathing.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants with at least one episode of oxygen desaturation (SpO2 ≤ 90%) during the procedure
Tijdsspanne: From the start to the end of the procedure (Day 0)
|
Oxygen desaturation is defined as a peripheral oxygen saturation (SpO2) ≤ 90%, regardless of its duration, measured by continuous pulse oximetry during the colonoscopy performed under general anesthesia. |
From the start to the end of the procedure (Day 0)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Total number of episodes of oxygen desaturation (SpO₂ ≤ 90%) during the procedure
Tijdsspanne: From the start to the end of the procedure (Day 0)
|
Number of desaturation episodes (SpO2 ≤ 90%) per participant, determined from continuously recorded pulse oximetry data. |
From the start to the end of the procedure (Day 0)
|
|
Cumulative duration of oxygen desaturation episodes (SpO2 ≤ 90%) relative to the total duration of the procedure
Tijdsspanne: From the start to the end of the procedure (Day 0)
|
Total time (in seconds) spent with SpO2 ≤ 90%, divided by the total duration of the procedure, i.e. the fraction of procedure time spent in desaturation (between 0 and 1), determined from continuously recorded pulse oximetry data. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of an episode of hypotension, defined as systolic blood pressure (SBP) < 100 mmHg, during the procedure
Tijdsspanne: From the start to the end of the procedure (Day 0)
|
Determined from continuously recorded non-invasive blood pressure data. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of an episode of severe bradycardia, defined as heart rate < 40 beats/minute, during the procedure
Tijdsspanne: From the start to the end of the procedure (Day 0)
|
Determined from continuously recorded heart rate data. |
From the start to the end of the procedure (Day 0)
|
|
Use of orotracheal intubation during the procedure
Tijdsspanne: From the start to the end of the procedure (Day 0)
|
Collected from the medical record and reported in the eCRF. |
From the start to the end of the procedure (Day 0)
|
|
Occurrence of a cardiac arrest during the procedure
Tijdsspanne: From the start to the end of the procedure (Day 0)
|
Cardiorespiratory arrest, collected from the medical record and reported in the eCRF |
From the start to the end of the procedure (Day 0)
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- APHP251722
- 2026-A00471-50 (Andere identificatie: IDRCB)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .